CHIMERIC ANTIGEN RECEPTORS TARGETING CD70

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic m...

Full description

Saved in:
Bibliographic Details
Main Authors PANOWSKI, Siler, SRIVATSA SRINIVASAN, Surabhi, SAI, Tao, NAGARAJAN, Niranjana Aditi, PARK, Yoon, SASU, Barbra Johnson, VAN BLARCOM, Thomas John, DUSSEAUX, Mathilde Brunnhilde, GALETTO, Roman Ariel
Format Patent
LanguageEnglish
French
German
Published 09.12.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
Bibliography:Application Number: EP20190709580